A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs XL 888 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Exelixis
  • Most Recent Events

    • 01 Apr 2011 Planned End Date changed from 1 Jul 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 May 2009 Actual initiation date changed from Feb 2009 to Nov 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top